<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32653439</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9649</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Ageing research reviews</Title><ISOAbbreviation>Ageing Res Rev</ISOAbbreviation></Journal><ArticleTitle>Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS.</ArticleTitle><Pagination><StartPage>101121</StartPage><MedlinePgn>101121</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arr.2020.101121</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1568-1637(20)30256-7</ELocationID><Abstract><AbstractText>A plethora of genetic and molecular mechanisms have been implicated in the pathophysiology of the heterogeneous and multifactorial amyotrophic lateral sclerosis (ALS) disease, and hence the conventional "one target-one drug" paradigm has failed so far to provide effective therapeutic solutions, precisely because of the complex nature of ALS. This review intends to highlight how the integration of emerging "omics" approaches may provide a rational foundation for the comprehensive exploration of molecular pathways and dynamic interactions involved in ALS, for the identification of candidate targets and biomarkers that will assist in the rapid diagnosis and prognosis, lastly for the stratification of patients into different subgroups with the aim of personalized therapeutic strategies. To this purpose, particular emphasis will be placed on some potential therapeutic targets, including neurotrophic factors and histamine signaling that both have emerged as dysregulated at different omics levels in specific subgroups of ALS patients, and have already shown promising results in in vitro and in vivo models of ALS. To conclude, we will discuss about the utility of using integrated omics coupled with network-based approaches to provide additional guidance for personalization of medicine applications in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volont&#xe9;</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CNR, Institute for Systems Analysis and Computer Science, Via Dei Taurini 19, 00185 Rome, Italy; IRCCS Fondazione Santa Lucia, Via Del Fosso di Fiorano 65, 00143 Rome, Italy. Electronic address: cinzia.volonte@cnr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morello</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CNR, Institute for Biomedical Research and Innovation, Via Paolo Gaifami, 18, 95126, Catania, Italy. Electronic address: gmorello@isn.cnr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spampinato</LastName><ForeName>Antonio Gianmaria</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>CNR, Institute for Biomedical Research and Innovation, Via Paolo Gaifami, 18, 95126, Catania, Italy. Electronic address: antoniogianmaria.spampinato@cnr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadio</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Via Del Fosso di Fiorano 65, 00143 Rome, Italy. Electronic address: s.amadio@hsantalucia.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apolloni</LastName><ForeName>Savina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Via Del Fosso di Fiorano 65, 00143 Rome, Italy. Electronic address: s.apolloni.phd@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agata</LastName><ForeName>Velia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Section of Human Anatomy and Histology, Department Biomedical and Biotechnological Sciences, University of Catania, Via Santa Sofia, 87, 95100 Catania, Italy. Electronic address: vdagata@unict.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavallaro</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CNR, Institute for Biomedical Research and Innovation, Via Paolo Gaifami, 18, 95126, Catania, Italy. Electronic address: sebastiano.cavallaro@cnr.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ageing Res Rev</MedlineTA><NlmUniqueID>101128963</NlmUniqueID><ISSNLinking>1568-1637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>820484N8I3</RegistryNumber><NameOfSubstance UI="D006632">Histamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006632" MajorTopicYN="N">Histamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Drug targets</Keyword><Keyword MajorTopicYN="N">Histamine</Keyword><Keyword MajorTopicYN="N">Multiomics</Keyword><Keyword MajorTopicYN="N">Network pharmacology</Keyword><Keyword MajorTopicYN="N">Neurotrophins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32653439</ArticleId><ArticleId IdType="doi">10.1016/j.arr.2020.101121</ArticleId><ArticleId IdType="pii">S1568-1637(20)30256-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>